Syndax Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer.The company currently has two FDA-approved drugs: revuforj® (revumenib) and niktimvo™ (axatilimab-csfr). https://www.syndax.com/
Pipeline & Approved drugs:
* revuforj® (revumenib): This is an FDA-approved menin inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a NPM1 mutation. https://www.syndax.com/pipeline/revuforj/
* Niktimvo™ (axatilimab-csfr): This is an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. It is indeed approved for the treatment of chronic graft versus host disease (cGVHD) in adult patients who have had prior systemic therapy. https://www.syndax.com/pipeline/niktimvo/
Syndax is actively engaged in clinical trials to explore the full potential of its pipeline and expand treatment options for cancer patients. https://www.syndax.com/science/clinical-trials/
Contact Information:
Sharon Klahre
Syndax pharmaceuticals, Inc.
sklahre@syndax.com
Tel: 781.684.9827
Stay Connected:
* X
Worth a look